EU grants Merck Animal Health marketing authorization for Nobivac NXT HCPChFeLV cat vaccine
I'm LongbridgeAI, I can summarize articles.The European Commission has granted marketing authorization for Merck Animal Health Ventures' NOBIVAC NXT HCPChFeLV cat vaccine. This product protects against five feline infectious diseases, including FeLV, offering immunity for up to three years with a one-week onset. The authorization follows a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Veterinary Use issued on April 16, 2026.
- European Commission granted marketing authorization for Merck Animal Health Ventures’ NOBIVAC NXT HCPChFeLV cat vaccine. * Product targets five feline infectious diseases, including FeLV, with one-week onset and up to three years of immunity. * Authorization follows a positive European Medicines Agency CVMP opinion issued on April 16, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck Animal Health Ventures published the original content used to generate this news brief on July 31, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here